Activating somatic mutations in the EGFR receptor tyrosine kinase are the most common targetable driver alterations identified in NSCLC, occurring in up to 16% patients with adenocarcinoma (8). The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.